Telomere length associations with cognition depend on Alzheimer's disease biomarkers
Abstract
While telomere shortening, a marker of cellular aging, may impact the progression of age‐related neurodegenerative diseases, its association with cognition is unclear, particularly in the context of Alzheimer's disease (AD) pathology.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2019
- Source ID
- 10.1016/j.trci.2019.11.003
Entities
People
- Andrew J. Saykin
- Angela J. Jefferson
- Emily R. Mahoney
- Katie A. Gifford
- Kelly N.h. Nudelman
- Logan Dumitrescu
- Mabel Seto
- Rachel F Buckley
- The Alzheimer’s Disease Neuroimaging Initiative*
- Timothy J. Hohman
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Indiana University
- Laboratoires Servier
- Lundbeck
- Massachusetts General Hospital
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- Vanderbilt University